Crinetics Pharmaceuticals, Inc. (CRNX)

Every figure this model derived for CRNX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,662,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 1,205,773,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,244,362,000 AssetsCurrent 2026-06-30
current liabilities 79,915,000 LiabilitiesCurrent 2026-06-30
equity 1,191,962,000 StockholdersEquity 2026-06-30
ocf -422,515,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 42,156,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 98,983,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CRNX on one particular measure came for.

RatioValue
cash operating margin-1057.66
current ratio15.9
current ratio reported15.57
dilution pct16.44
fcf margin-1008.58
growth cv4.49
operating margin-1302.52
owner earnings margin-1243.38
revenue growth2928.45
revenue growth per share2500.78
rule of 401625.93
sbc pct revenue234.8

What to be careful about

What this model itself distrusts about CRNX's figures. Written by the derivation as it ran, not added afterwards.